Erythropoietin, a novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitus

Wound Repair and Regeneration

Volumn 22, Issue 1, 2014, Pages 23-33

  Hamed, Saher ^a   Bennett, Charles L ^b   Demiot, Claire ^c   Ullmann, Yehuda ^c   Teot, Luc ^d   Desmoulière, Alexis ^e  

^a REMEDOR Biomed Ltd   (Israel)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF LIMOGES   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e Rambam Health Care Campus ^*  (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

APOPTOSIS; BURN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROTECTION; CHRONIC WOUND; DIABETES MELLITUS; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INJURY; TISSUE REGENERATION; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, EXPERIMENTAL; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; REGENERATIVE MEDICINE; SKIN; WOUND HEALING; WOUNDS AND INJURIES;

EID: 84891837106     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12135     Document Type: Review

References (97)

1. Scott Gavura. Available at http://www.sciencebasedmedicine.org/what-does- a-new-drug-cost-part-ii-the-productivity-problem (accessed December 20, 2012).
2. Allison M,. NCATS launches drug repurposing program. Nat Biotechnol 2012; 30: 571-572.
3. FDA. Erythropoietin. Available at http://www.accessdata.fda.gov (accessed September 9, 2012).
4. Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38: 845-853.
5. Galeano M, Altavilla D, Cucinotta D, Russo GT, Calo M, Bitto A, et al. Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetes 2004; 53: 2509-2517.
6. Hamed S, Ullmann Y, Masoud M, Hellou E, Khamaysi Z, Teot L,. Topical erythropoietin promotes wound repair in diabetic rats. J Invest Dermatol 2010; 130: 287-294.
7. Hamed S, Ullmann Y, Egozi D, Daod E, Hellou E, Ashkar M, et al. Fibronectin potentiates topical erythropoietin-induced wound repair in diabetic mice. J Invest Dermatol 2011; 6: 1365-1374.
8. Clark RA,. Cutaneous tissue repair: basic biologic considerations. I. J Am Acad Dermatol 1985; 13: 701-725.
9. Wong DJ, Chang HY,. Skin tissue engineering in stembook [Internet]. Cambridge, MA: Harvard Stem Cell Institute, 2008: ISSN:1940-3429.
10. Jahoda CA, Reynolds AJ,. Hair follicle dermal sheath cells: unsung participants in wound healing. Lancet 2001; 358: 1445-1448.
11. Sellheyer K, Krahl D,. Skin mesenchymal stem cells: prospects for clinical dermatology. J Am Acad Dermatol 2010; 63: 859-865.
12. Stadelmann WK, Digenis AG, Tobin GR,. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg 1998; 176: 26S-38S.
13. Valacchi G, Zanardi I, Sticozzi C, Bocci V, Travagli V,. Emerging topics in cutaneous wound repair. Ann N Y Acad Sci 2012; 1259: 136-144.
14. Gurtner GC, Werner S, Barrandon Y, Longaker MT,. Wound repair and regeneration. Nature 2008; 453: 314-321.
15. Quinn JV, Wells GA,. An assessment of clinical wound evaluation scales. Acad Emerg Med 1998; 5: 583-586.
16. Rodero MP, Khosrotehrani K,. Skin wound healing modulation by macrophages. Int J Clin Exp Pathol 2010; 3: 643-653.
17. Gillitzer R, Goebeler M,. Chemokines in cutaneous wound healing. J Leukoc Biol 2001; 69: 513-521.
18. Eichler MJ, Carlson MA,. Modeling dermal granulation tissue with the linear fibroblast-populated collagen matrix: a comparison with the round matrix model. J Dermatol Sci 2006; 41: 97-108.
19. Hinz B,. The myofibroblast: paradigm for a mechanically active cell. J Biomech 2010; 43: 146-155.
20. Martin P,. Wound healing-aiming for perfect skin regeneration. Science 1997; 276: 75-81.
21. Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007; 117: 1249-1259.
22. Falanga V,. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366: 1736-1743.
23. Witte MB, Barbul A,. Role of nitric oxide in wound repair. Am J Surg 2002; 183: 406-412.
24. Patel GK, Wilson CH, Harding KG, Finlay AY, Bowden PE,. Numerous keratinocyte subtypes involved in wound re-epithelialization. J Invest Dermatol 2006; 126: 497-502.
25. Desmoulière A, Redard M, Darby I, Gabbiani G,. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995; 146: 56-66.
26. Singer AJ, Clark RA,. Cutaneous wound healing. N Engl J Med 1999; 341: 738-746.
27. Blakytny R, Jude E,. The molecular biology of chronic wounds and delayed healing in diabetes. Diabetic Med 2006; 23: 594-608.
28. Sfredel V, Mota M, Traila A, Danoiu S, Matcas H,. Disturbances of the coagulating equilibrium of blood in diabetes mellitus. Rom J Intern Med 1999; 37: 251-260.
29. Labat-Robert J, Leutenegger M, Llopis G, Ricard Y, Derouette JC,. Plasma and tissue fibronectin in diabetes. Clin Physiol Biochem 1984; 2: 39-48.
30. Wysocki AB, Grinnell F,. Fibronectin profiles in normal and chronic wound fluid. Lab Invest 1990; 63: 825-831.
31. Doupis J, Rahangdale S, Gnardellis C, Pena SE, Malhotra A, Veves A,. Effects of diabetes and obesity on vascular reactivity, inflammatory cytokines, and growth factors. Obesity 2011; 19: 729-735.
32. Boulton AJ,. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev 2008; 24 (Suppl. 1): S3-S6.
33. Skljarevski V, Veves A,. Impact of diabetes on vasculature: focus on nervous system. Curr Diabetes Rev 2005; 1: 245-253.
34. Demiot C, Tartas M, Fromy B, Abraham P, Saumet JL, Sigaudo-Roussel D,. Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes 2006; 55: 1478-1483.
35. Mansbridge JN, Liu K, Pinney RE, Patch R, Ratcliffe A, Naughton GK,. Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes Obes Metab 1999; 1: 265-279.
36. Miyake T, Kung CK, Goldwasser E,. Purification of human erythropoietin. J Biol Chem 1997; 252: 5558-5564.
37. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-810.
38. Moore E, Bellomo R,. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care 2011; 1: 1-3.
39. Jelkmann W,. Biology of erythropoietin. Clin Investig 1994; 72: S3-10.
40. Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul-Nour T, Bartmann P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 1998; 92: 3218-3225.
41. Koury ST, Bondurant MC, Koury MJ, Semenza GL,. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991; 77: 2497-2503.
42. Maiese K, Li F, Chong ZZ,. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95.
43. Arcasoy MO,. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31.
44. Brines M, Cerami A,. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70: 246-250.
45. Brines M,. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 2010; 29: 86-92.
46. Su KH, Shyue SK, Kou YR, Ching LC, Chiang AN, Yu YB, et al. β common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol 2011; 226: 3330-3339.
47. Bader A, Machens HG,. Recombinant human erythropoietin plays a pivotal role as a topical stem cell activator to reverse effects of damage to the skin in aging and trauma. Rejuvenation Res 2010; 13: 499-500.
48. Malyszko J, Malyszko JS, Borawski J, Rydzewski A, Kalinowski M, Azzadin A, et al. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995; 77: 133-143.
49. Fuste B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 678-685.
50. Stasko J, Drouet L, Soria C, Mazoyer E, Caen J, Kubisz P,. Erythropoietin and granulocyte colony-stimulating factor increase plasminogen activator inhibitor-1 release in HUVEC culture. Thromb Res 2002; 105: 161-164.
51. Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004; 10: 225-232.
52. Brines M, Cerami A,. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008; 264: 405-432.
53. Sorg H, Krueger C, Schulz T, Menger MD, Schmitz F, Vollmar B,. Effects of erythropoietin in skin wound healing are dose related. FASEB J 2009; 23: 3049-3058.
54. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999; 19: 643-651.
55. Strunk T, Hartel C, Temming P, Matzke N, Zimmer J, Schultz C,. Erythropoietin inhibits cytokine production of neonatal and adult leukocytes. Acta Paediatr 2008; 97: 16-20.
56. Nairz M, Schroll A, Moschen AR, Sonnweber T, Theurl M, Theurl I, et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity 2011; 34: 61-74.
57. Erbayraktar Z, Erbayraktar S, Yilmaz O, Cerami A, Coleman T, Brines M,. Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Mol Med 2009; 15: 235-241.
58. Ghezzi P, Brines M,. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2004; 11: S37-44.
59. Bodo E, Kromminga A, Funk W, Laugsch M, Duske U, Jelkmann W,. Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin. FASEB J 2007; 21: 3346-3354.
60. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994; 91: 3974-3978.
61. Alvarez Arroyo MV, Castilla MA, Gonzalez Pacheco FR, Tan D, Riesco A, Casado S, et al. Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation. J Am Soc Nephrol 1998; 9: 1998-2004.
62. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-1346.
63. Chen L, Tredget EE, Wu PY, Wu Y,. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 2008; 3: e1886.
64. Santhanam AV, d'Uscio LV, Peterson TE, Katusic ZS,. Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 2008; 29: 1451-1455.
65. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-926.
66. Piek E, Heldin CH, Ten Dijke P,. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 1999; 13: 2105-2124.
67. Siebert N, Xu W, Grambow E, Zechner D, Vollmar B,. Erythropoietin improves skin wound healing and activates the TGF-β signaling pathway. Lab Invest 2011; 91: 1753-1765.
68. Sarrazy V, Billet F, Micallef L, Coulomb B, Desmoulière A,. Mechanisms of pathological scarring: role of myofibroblasts and current developments. Wound Repair Regen 2011; 19 (Suppl. 1): s10-15.
69. Yang B, Hosgood SA, Bagul A, Waller HL, Nicholson ML,. Erythropoietin regulates apoptosis, inflammation and tissue remodelling via caspase-3 and IL-1β in isolated hemoperfused kidneys. Eur J Pharmacol 2011; 660: 420-430.
70. Fatouros M, Dalekos GN, Mylonakis E, Vekinis G, Kappas AM,. Alterations in body weight, breaking strength, and wound healing in Wistar rats treated pre- and postoperatively with erythropoietin or granulocyte macrophage-colony stimulating factor: evidence of a previously unknown anabolic effect of erythropoietin? J Lab Clin Med 1999; 133: 253-259.
71. Haroon ZA, Amin K, Jiang X, Arcasoy MO,. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 2003; 163: 993-1000.
72. Buemi M, Vaccaro M, Sturiale A, Galeano MR, Sansotta C, Cavallari V, et al. Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps. Acta Derm Venereol 2002; 82: 411-417.
73. Buemi M, Galeano M, Sturiale A, Ientile R, Crisafulli C, Parisi A, et al. Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock 2004; 22: 169-173.
74. Sayan H, Ozacmak VH, Guven A, Aktas RG, Ozacmak ID,. Erythropoietin stimulates wound healing and angiogenesis in mice. J Invest Surg 2006; 19: 163-173.
75. Elsherbiny A, Hogger DC, Borozadi MK, Schmidt CA, Plock J, Largo RD, et al. EPO reverses defective wound repair in hypercholesterolaemic mice by increasing functional angiogenesis. J Plast Reconstr Aesthet Surg 2012; 65: 1559-1568.
76. Galeano M, Altavilla D, Bitto A, Minutoli L, Calo M, Lo Cascio P, et al. Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med 2006; 34: 1139-1146.
77. Tobalem M, Harder Y, Schuster T, Rezaeian F, Wettstein R,. Erythropoietin in the prevention of experimental burn progression. Br J Surg 2012; 99: 1295-1303.
78. Tobalem M, Harder Y, Rezaeian F, Wettstein R,. Secondary burn progression decreased by erythropoietin. Crit Care Med 2013; 41: 963-971.
79. Bohr S, Patel SJ, Shen K, Vitalo AG, Brines M, Cerami A, et al. Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns. Proc Natl Acad Sci U S A 2013; 26: 3513-3518.
80. Bader A, Ebert S, Giri S, Kremer M, Liu S, Nerlich A, et al. Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO. Int J Nanomed 2012; 7: 1227-1237.
81. Eming SA, Brachvogel B, Odorisio T, Koch M,. Regulation of angiogenesis: wound healing as a model. Prog Histochem Cytochem 2007; 42: 115-170.
82. Kim EK, Hong JP,. The effect of recombinant human erythropoietin on ischemia-reperfusion injury: an experimental study in a rat TRAM flap model. Plast Reconstr Surg 2007; 120: 1774-1781.
83. Keast DH, Fraser C,. Treatment of chronic skin ulcers in individuals with anemia of chronic disease using recombinant human erythropoietin (EPO): a review of four cases. Ostomy Wound Manage 2004; 50: 64-70.
84. Ferri C, Giuggioli D, Sebastiani M, Colaci M,. Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin. Clin Exp Dermatol 2007; 32: 287-290.
85. Ferri C, Giuggioli D, Manfredi A, Quirici N, Scavullo C, Colaci M, et al. Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers. Clin Exp Dermatol 2010; 35: 885-887.
86. Bader A, Lorenz K, Richter A, Scheffler K, Kern L, Ebert S, et al. Interactive role of trauma cytokines and erythropoietin and their therapeutic potential for acute and chronic wounds. Rejuvenation Res 2011; 14: 57-66.
87. Gunter CI, Bader A, Dornseifer U, Egert S, Sebastian D, Grieb G, et al. A multi-center study on the regenerative effects of erythropoietin in burn and scalding injuries: study protocol for a randomized controlled trial. Trials 2013; 14: 124-132.
88. Siren AL, Fasshauer T, Bartels C, Ehrenreich H,. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurother 2009; 6: 108-127.
89. Cao Y,. Erythropoietin in cancer: a dilemma in risk therapy. Trends Endocrinol Metab 2013; 24: 190-199.
90. Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, et al. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38: 783-796.
91. Crovetti G, Martinelli G, Issi M, Barone M, Guizzardi M, Campanati B, et al. Platelet gel for healing cutaneous chronic wounds. Transfus Apher Sci 2004; 30: 145-151.
92. Gottrup F,. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg 2004; 187: 38S-43S.
93. Center for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, CfDCaPCenters for Disease Control and Prevention, 2008.
94. Stillman RM,. Diabetic ulcers. eMedicine from WebMD. 2008. Available at http://www.emedicine.com/med/topic551.htm (accessed November 23, 2012).
95. Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 2009; 17: 763-771.
96. Erythropoietin. Available at http://www.ncats.nih.gov/research/ reengineering/rescue-repurpose/rescue-repurpose.html (accessed August 18, 2013).
97. Moran M, Ozmen MM, Duzgun AP, Gok R, Renda N, Seckin S, et al. The effect of erythropoietin on healing of obstructive vs nonobstructive left colonic anastomosis: an experimental study. World J Emerg Surg 2007; 2: 13-19.